Lifecore Biomedical (LFCR) to Release Earnings on Monday

Lifecore Biomedical (NASDAQ:LFCR) is projected to announce its Q4 2025 results before the market opens on Monday, August 25th. Analysts expect Lifecore Biomedical to post earnings of ($0.09) per share and revenue of $35.3630 million for the quarter. Lifecore Biomedical has set its FY 2026 guidance at EPS.Interested persons can check the company’s upcoming Q4 2025 earningsummary page for the latest details on the call scheduled for Thursday, August 7, 2025 at 4:30 PM ET.

Lifecore Biomedical (NASDAQ:LFCR) last issued its earnings results on Thursday, August 7th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). The company had revenue of $36.44 million for the quarter, compared to the consensus estimate of $35.36 million. Lifecore Biomedical had a negative return on equity of 846.51% and a negative net margin of 31.70%. On average, analysts expect Lifecore Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lifecore Biomedical Stock Performance

LFCR opened at $7.60 on Friday. The company has a debt-to-equity ratio of 113.76, a quick ratio of 1.77 and a current ratio of 2.84. The stock has a market capitalization of $284.30 million, a price-to-earnings ratio of -5.80 and a beta of 0.65. The company has a fifty day moving average of $7.58 and a 200 day moving average of $6.81. Lifecore Biomedical has a fifty-two week low of $3.68 and a fifty-two week high of $8.85.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on LFCR. Wall Street Zen upgraded Lifecore Biomedical from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. William Blair began coverage on shares of Lifecore Biomedical in a report on Wednesday, May 21st. They issued an “outperform” rating for the company. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Insider Activity at Lifecore Biomedical

In other Lifecore Biomedical news, major shareholder Aron R. English sold 1,139,504 shares of Lifecore Biomedical stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $6.50, for a total transaction of $7,406,776.00. Following the completion of the transaction, the insider directly owned 414,599 shares of the company’s stock, valued at $2,694,893.50. The trade was a 73.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 32.20% of the company’s stock.

Institutional Investors Weigh In On Lifecore Biomedical

Several hedge funds and other institutional investors have recently made changes to their positions in the company. State of Wyoming purchased a new position in shares of Lifecore Biomedical during the 2nd quarter worth about $69,000. The Manufacturers Life Insurance Company purchased a new stake in Lifecore Biomedical in the 2nd quarter worth about $88,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Lifecore Biomedical by 14.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company’s stock worth $104,000 after purchasing an additional 1,886 shares during the last quarter. Rhumbline Advisers lifted its stake in Lifecore Biomedical by 54.0% in the second quarter. Rhumbline Advisers now owns 38,091 shares of the company’s stock worth $309,000 after purchasing an additional 13,361 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in shares of Lifecore Biomedical by 16.8% during the first quarter. Goldman Sachs Group Inc. now owns 87,998 shares of the company’s stock valued at $620,000 after buying an additional 12,647 shares during the period. Hedge funds and other institutional investors own 83.36% of the company’s stock.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.